1628810-38-7 Usage
Description
(R)-3-(2,5-difluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one is a synthetic chemical compound with the molecular formula C9H8F3N3O2. It is characterized by its potent antimicrobial properties and is utilized in the treatment of various bacterial infections.
Uses
Used in Pharmaceutical Industry:
(R)-3-(2,5-difluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one is used as an antimicrobial agent for treating a range of bacterial infections. Its application is particularly significant in combating methicillin-resistant Staphylococcus aureus (MRSA) and other multidrug-resistant bacterial infections. (R)-3-(2,5-difluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one works by inhibiting bacterial protein synthesis, thereby disrupting the bacteria's growth and ultimately leading to their death.
Used in Development of New Antibiotics:
(R)-3-(2,5-difluoropyrimidin-4-yl)-4-(fluoromethyl)oxazolidin-2-one serves as an important tool in the development of novel antibiotics. Its potent inhibitory effect on bacterial protein synthesis makes it a valuable component in the creation of new drugs to address the growing issue of drug-resistant bacterial infections.
Check Digit Verification of cas no
The CAS Registry Mumber 1628810-38-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,2,8,8,1 and 0 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1628810-38:
(9*1)+(8*6)+(7*2)+(6*8)+(5*8)+(4*1)+(3*0)+(2*3)+(1*8)=177
177 % 10 = 7
So 1628810-38-7 is a valid CAS Registry Number.
1628810-38-7Relevant articles and documents
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors
Zhao, Qian,Manning, James R.,Sutton, James,Costales, Abran,Sendzik, Martin,Shafer, Cynthia M.,Levell, Julian R.,Liu, Gang,Caferro, Thomas,Cho, Young Shin,Palermo, Mark,Chenail, Gregg,Dooley, Julia,Villalba, Brian,Farsidjani, Ali,Chen, Jinyun,Dodd, Stephanie,Gould, Ty,Liang, Guiqing,Slocum, Kelly,Pu, Minying,Firestone, Brant,Growney, Joseph,Heimbach, Tycho,Pagliarini, Raymond
, p. 746 - 751 (2018)
Mutant isocitrate dehydrogenase 1 (IDH1) is an attractive therapeutic target for the treatment of various cancers such as AML, glioma, and glioblastoma. We have evaluated 3-pyrimidin-4-yl-oxazolidin-2-ones as mutant IDH1 inhibitors that bind to an allosteric, induced pocket of IDH1R132H. This Letter describes SAR exploration focused on improving both the in vitro and in vivo metabolic stability of the compounds, leading to the identification of 19 as a potent and selective mutant IDH1 inhibitor that has demonstrated brain penetration and excellent oral bioavailability in rodents. In a preclinical patient-derived IDH1 mutant xenograft tumor model study, 19 efficiently inhibited the production of the biomarker 2-HG.
